Literature DB >> 30985546

Predictors of Perinatal HIV Transmission Among Women Without Prior Antiretroviral Therapy in a Resource-Limited Setting: The Breastfeeding, Antiretrovirals and Nutrition Study.

Alexander C Ewing1, Sascha R Ellington1, Jeffrey B Wiener1, Charles S Chasela2, Gerald Tegha3, Julie A E Nelson4, Denise J Jamieson1, Charles van der Horst4, Athena P Kourtis1.   

Abstract

BACKGROUND: To investigate potential risk factors for perinatal (intrauterine and intrapartum) mother-to-child transmission (MTCT) of HIV in women unexposed to antiretroviral therapy (ART) during pregnancy.
METHODS: We compared factors according to perinatal MTCT outcome among 2275 ART-naive (until the onset of labor) HIV-infected women in the Breastfeeding, Antiretrovirals and Nutrition study (2004-2010) in Lilongwe, Malawi. Factors included HIV viral load during pregnancy, food security, demographic characteristics, hematologic and blood chemistry measures, medical history and physical factors. Associations with perinatal MTCT and interactions with maternal viral load were assessed using simple and multivariable logistic regression.
RESULTS: There were 119 (115 intrauterine and 4 intrapartum) cases of perinatal MTCT, only one to a mother with <1000 HIV copies/mL. Maternal viral loads >10,000 copies/mL were common (63.1%). Lower maternal viral load (<1000 copies/mL and 1000.1-10,000 copies/mL) was associated with reduced odds of perinatal MTCT [adjusted odds ratio (aOR), 0.1; 95% confidence interval (CI): 0.01-0.4 and aOR, 0.2; 95% CI: 0.1-0.4, respectively), compared with maternal viral load >10,000 copies/mL. Low CD4+ T cell count (≤350 cells/μL) was only associated with perinatal MTCT in unadjusted models. Food shortage (aOR, 1.8; 95% CI: 1.2-2.6), sexually transmitted infection (STI) (past year; aOR, 1.9; 95% CI: 1.0-3.7), histories of herpes zoster (aOR, 3.0; 95% CI: 1.6-5.6) and tuberculosis (aOR, 2.5; 95% CI: 1.1-5.7) were associated with increased odds of perinatal MTCT.
CONCLUSIONS: These findings confirm that lowering maternal HIV viral load is most important in preventing perinatal MTCT and support efforts to address food shortage, STI and tuberculosis prevention, while informing programs to improve ART coverage in pregnancy.

Entities:  

Mesh:

Year:  2019        PMID: 30985546      PMCID: PMC6481191          DOI: 10.1097/INF.0000000000002220

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  39 in total

1.  Serum albumin as a predictor of survival in HIV-infected women in the Women's Interagency HIV study.

Authors:  J G Feldman; D N Burns; S J Gange; P Bacchetti; M Cohen; K Anastos; M Nowicki; R Delapena; P Miotti
Journal:  AIDS       Date:  2000-05-05       Impact factor: 4.177

2.  Herpes zoster in African patients: a clinical predictor of human immunodeficiency virus infection.

Authors:  R Colebunders; J M Mann; H Francis; K Bila; L Izaley; M Ilwaya; N Kakonde; T C Quinn; J W Curran; P Piot
Journal:  J Infect Dis       Date:  1988-02       Impact factor: 5.226

3.  Syphilis among HIV-infected mothers and their infants in Texas from 1988 to 1994.

Authors:  J M Schulte; S Burkham; D Hamaker; M E St Louis; J M Paffel; D Hutcheson; M B Caldwell; K L Dominguez; W C Levine
Journal:  Sex Transm Dis       Date:  2001-06       Impact factor: 2.830

4.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Authors:  Ellen R Cooper; Manhattan Charurat; Lynne Mofenson; I Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

5.  Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team.

Authors:  L M Mofenson; J S Lambert; E R Stiehm; J Bethel; W A Meyer; J Whitehouse; J Moye; P Reichelderfer; D R Harris; M G Fowler; B J Mathieson; G J Nemo
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

6.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Authors:  P M Garcia; L A Kalish; J Pitt; H Minkoff; T C Quinn; S K Burchett; J Kornegay; B Jackson; J Moye; C Hanson; C Zorrilla; J F Lew
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

7.  Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: the French perinatal cohort studies. SEROGEST Cohort Group.

Authors:  M J Mayaux; E Dussaix; J Isopet; C Rekacewicz; L Mandelbrot; N Ciraru-Vigneron; M C Allemon; V Chambrin; C Katlama; J F Delfraissy; J Puel
Journal:  J Infect Dis       Date:  1997-01       Impact factor: 5.226

Review 8.  Nutrition and maternal, neonatal, and child health.

Authors:  Parul Christian; Luke C Mullany; Kristen M Hurley; Joanne Katz; Robert E Black
Journal:  Semin Perinatol       Date:  2015-07-10       Impact factor: 3.300

9.  Maternal herpes simplex virus type 2 coinfection increases the risk of perinatal HIV transmission: possibility to further decrease transmission?

Authors:  Liesbeth Jm Bollen; Sara J Whitehead; Philip A Mock; Wanna Leelawiwat; Suvanna Asavapiriyanont; Amphan Chalermchockchareonkit; Nirun Vanprapar; Tawee Chotpitayasunondh; Janet M McNicholl; Jordan W Tappero; Nathan Shaffer; Rutt Chuachoowong
Journal:  AIDS       Date:  2008-06-19       Impact factor: 4.177

10.  Maternal vitamin A deficiency and mother-to-child transmission of HIV-1.

Authors:  R D Semba; P G Miotti; J D Chiphangwi; A J Saah; J K Canner; G A Dallabetta; D R Hoover
Journal:  Lancet       Date:  1994-06-25       Impact factor: 79.321

View more
  4 in total

1.  Perinatal Food Insecurity and Postpartum Psychosocial Stress are Positively Associated Among Kenyan Women of Mixed HIV Status.

Authors:  Pamela M Murnane; Joshua D Miller; Emily L Tuthill; Shalean M Collins; Torsten B Neilands; Maricianah Onono; Craig R Cohen; Sheri D Weiser; Mark L Laudenslager; Sera L Young
Journal:  AIDS Behav       Date:  2020-06

2.  Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.

Authors:  Esaú C João; R Leavitt Morrison; David E Shapiro; Nahida Chakhtoura; Maria Isabel S Gouvèa; Maria de Lourdes B Teixeira; Trevon L Fuller; Blandina T Mmbaga; James S Ngocho; Boniface N Njau; Avy Violari; Ruth Mathiba; Zaakirah Essack; Jose Henrique S Pilotto; Luis Felipe Moreira; Maria Jose Rolon; Pedro Cahn; Sinart Prommas; Timothy R Cressey; Kulkanya Chokephaibulkit; Peerawong Werarak; Lauren Laimon; Roslyn Hennessy; Lisa M Frenkel; Patricia Anthony; Brookie M Best; George K Siberry; Mark Mirochnick
Journal:  Lancet HIV       Date:  2020-05       Impact factor: 12.767

3.  Mother-to-Child HIV Transmission With In Utero Dolutegravir vs. Efavirenz in Botswana.

Authors:  Sonya Davey; Gbolahan Ajibola; Kenneth Maswabi; Maureen Sakoi; Kara Bennett; Michael D Hughes; Arielle Isaacson; Modiegi Diseko; Rebecca Zash; Oganne Batlang; Sikhulile Moyo; Shahin Lockman; Mathias Lichterfeld; Daniel R Kuritzkes; Joseph Makhema; Roger Shapiro
Journal:  J Acquir Immune Defic Syndr       Date:  2020-07-01       Impact factor: 3.771

4.  The challenge of using nanotherapy during pregnancy: Technological aspects and biomedical implications.

Authors:  Kelle Velasques Pereira; Renata Giacomeli; Marcelo Gomes de Gomes; Sandra Elisa Haas
Journal:  Placenta       Date:  2020-08-18       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.